Lupus & antiphospholipid syndrome
Hydroxychloroquine Associated With Lower Glomerular Filtration Rate Decline in Lupus Nephritis
Authors' conclusion
HCQ use was associated with early and long-term benefits on kidney function in LN, including those with CKD stage ≥3.
Study context
- Population
- Patients with incident biopsy-proven lupus nephritis (LN), followed from LN diagnosis
- Participants
- 209 patients
- Exposure
- Time-varying hydroxychloroquine (HCQ) exposure vs no HCQ exposure
- Outcome
- Sustained eGFR decline ≥30% and ≥40%
Methodological detailsinception cohort, biopsy-proven LN, HCQ exposure as time-dependent covariate, propensity score adjusted, linear mixed-effects analysis
- Inception cohort
- Biopsy-proven LN
- HCQ exposure as time-dependent covariate
- Propensity score adjusted
- Linear mixed-effects analysis
Main finding
As reported in the abstract
Sustained eGFR decline ≥30% or ≥40%
Lower risk of estimated glomerular filtration rate (eGFR) decline ≥30% with time-varying HCQ exposure
60%
Lower risk of eGFR decline ≥40% with time-varying HCQ exposure
62%
eGFR decline ≥30% over time (all patients)
33%
eGFR decline ≥40% over time (all patients)
23%
Observational data: associations, not effects.
Further findings
eGFR decline in chronic kidney disease (CKD) stage ≥3 (subgroup)
- Lower risk of eGFR decline with HCQ
- 77%
Annual eGFR slope decline · first 5 and 10 years of diagnosis
mL/min/1.73 m²
- Reduction in annual eGFR slope decline with HCQ, first 5 years
- 5.12
- Reduction in annual eGFR slope decline with HCQ, first 10 years
- 3.17
Original publication
Hydroxychloroquine Associated With Lower Glomerular Filtration Rate Decline in Lupus Nephritis. Arthritis Care Res (Hoboken). Published 22 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →